At baseline, eligible participants were randomized 4:1 to receive intravenous ARGX-119 or placebo ... and Associate Professor Maartje Huijbers from LUMC. argenx is a global immunology company ...

Phase 1b study supports proof-of-concept in DOK7 congenital myasthenic syndromes Advancing ARGX-119 further validates strong track record of Immunology Innovation Program (IIP), argenx's collaborative ...

"We have shown that sClever-1 operates independently of the cellular receptor and contributes to an immunosuppressive environment. This discovery not only deepens our understanding of cancer ...

NB.1.8.1 is one of the latest variants of COVID-19, a "slightly upgraded version" of the LP.8.1 variant that is prominent ...

A letter to the US public on the AMA website, signed by 75+ medical societies, stresses the vital importance of influenza, RSV, and COVID-19 vaccines.

Giving parents current guidelines on early introduction of peanut, egg, and cow’s milk significantly reduces babies’ ...

A new COVID-19 variant is spreading rapidly through the U.S. What to know about NB.1.8.1 and its symptoms in Tennessee.

DBV Technologies Announces First Subject Screened in COMFORT Toddlers Supplemental Safety Study in Peanut Allergic Toddlers 1 – 3 Years Old First subject screened at the Respiratory Medicine Research ...

Adults on dupilumab for severe chronic rhinosinusitis with nasal polyps had better outcomes than those who used omalizumab, ...

Kymera Therapeutics, Inc.'s stock rose on KT-621 data, but Sanofi's exit casts doubts. A Gilead Sciences, Inc. deal offers ...

Misbehaving T cells light up long before Parkinson’s symptoms show, zeroing in on vulnerable brain proteins. Their early surge could double as an alarm bell and a target for stop-it-early treatments.